Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05968963

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Stem Cell Transplantation Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myeloid, Acute Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Myelodysplastic Syndromes Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Miami

Miami, Florida, 33136, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years of age
  • have a primary diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or non Hodgkin's Lymphoma (NHL)
  • have a treatment plan for an allogeneic hematopoietic stem cell transplant
  • Speak English or Spanish

Exclusion criteria

  • history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)
  • severe cognitive impairment (per the short portable mental status questionnaire)
  • hearing impairment
  • active alcohol or substance dependence within the past six months
  • participated in music therapy or mindfulness programs in the past six months

Treatment and study plan

Mindfulness-based Music Therapy (MBMT)

Behavioral

Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.

Mindfulness Meditation (MM)

Behavioral

Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.

Primary outcomes

  1. Count of Participants Recruited

    Time frame: Baseline (T1)

    Recruitment will be measured by the count of participants successfully recruited and randomized into the study.

  2. Number of Participants Retained

    Time frame: Up to 18 months

    Participant retention will be examined via the number of participants retained in the study.

  3. Mean Number of Intervention Sessions that Participants Completed

    Time frame: Up to 100 days post-transplant

    Participant engagement will be examined via the mean number of intervention sessions completed by participants measured after the 8th (and last) intervention session which is given between 75 and 100 days post-transplant.

  4. Satisfaction Scores as Measured by Weekly Rating Satisfaction Score

    Time frame: Up to 100 days post-transplant

    Scores per item range from 0 to 5. Higher scores indicate more satisfaction.

Secondary outcomes

  1. Change in Health Related Quality of Life Scores as Measures by Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)

    Time frame: Baseline (T1), up to 18 months

    FACT-BMT score range 0-164, with higher scores indicating better quality of life.

  2. Change in Pain as Measured by patient reported outcome measures (PROMIS®) pain scale.

    Time frame: Baseline (T1), up to 18 months

    (PROMIS®) pain scale is scored on a range of 3 to 15 with higher scores indicating higher pain.

  3. Change in Fatigue as Measured by patient reported outcome measures (PROMIS®) Fatigue scale.

    Time frame: Baseline (T1), up to 18 months

    (PROMIS®) Fatigue scale is scored on a range of 8 to 40. Higher scores indicate higher fatigue.

  4. Change in Cognitive Function Scores as Measured by The Repeatable Battery for the Assessment of Neuropsychological Status.

    Time frame: Baseline (T1), up to 18 months

    The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores range from 40-160 with higher scores indicating better cognitive function.

  5. Change in Sleep Quality Scores as Measured by Pittsburgh Sleep Quality Index

    Time frame: Baseline (T1), up to 18 months

    Pittsburgh Sleep Quality Index score range from 0 to 21. Higher score indicate worse sleep quality.

  6. Number of Days to Engraftment Measured from Infusion to Engraftment.

    Time frame: Up to 18 months

    To measure the number of days to engraftment we will extract from the electronic medical record (EMR) days from infusion to engraftment.

  7. Number of Days of Hospitalization Measured from Admission to Engraftment.

    Time frame: Up to 18 months

    To measure the number of days of hospitalization we will extract from the electronic medical record (EMR) days of hospitalization from admission to engraftment.

  8. Number of Hospital Readmissions after Hospital Discharge

    Time frame: Up to 100 days

    To measure the number of hospital readmissions we will extract from the electronic medical record (EMR) the number of hospital readmissions from hospital discharge.

  9. Number of Infections from Hospital Admission

    Time frame: up to 100 Days Post-Infusion Day

    To measure the number of infections we will extract from the electronic medical record (EMR) the number of infections from hospital admission measure up to 100 days post infusion.

  10. Change in anxiety Scores as Measured with the Generalized anxiety disorder (GAD-7)

    Time frame: Baseline (T1), up to 18 months

    Generalized anxiety disorder (GAD-7) range is 0 to 21; higher score is associated with more severe anxiety.

  11. Changes in Depression Scores as measured with the patient health questionnaire (PHQ-9)

    Time frame: Baseline (T1), up to 18 months

    PHQ-9 (patient health questionnaire) score range is from 0 to 27; higher score is associated with more severe depression.

  12. Change in Cancer-specific Distress Scores as Measured by the Impact of Events Scale-Revised

    Time frame: Baseline (T1), up to 18 months

    Impact of Events Scale-Revised range is 0 to 88; higher score is associated with more effect caused by events.

  13. Change in Serum Cortisol as Measured by ELISA

    Time frame: Baseline (T1), up to 18 months

    Serum cortisol levels are measured via ELISA. Serum Cortisol normal levels morning range: 10-20 mcg/dL ; afternoon range: 3-10 mcg/dL. Any values outside of the range are associated with higher stress and inflammation

  14. Change in Immunocompetence as Measured by Cytokines

    Time frame: Baseline (T1), up to 18 months

    Cytokines levels are measured in pg/mL. Any values outside of the normal range are associated with inflammation

  15. Change in Immunocompetence as Measured by Thymic Function

    Time frame: Baseline (T1), up to 18 months

    Thymic function T-cell receptor excision circles (TRECs) measured by TRECs/microliter.

  16. Change in Immunocompetence as Measured by Regulatory T cells

    Time frame: Baseline (T1), up to 18 months

    Regulatory T cells measured as cells/mm^3

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Aug 1, 2023
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.